Tirzepatide Achieves Cardiovascular Noninferiority Against Dulaglutide: A Milestone in Dual Incretin Therapy
Posted inCardiology Diabetes & Endocrinology news

Tirzepatide Achieves Cardiovascular Noninferiority Against Dulaglutide: A Milestone in Dual Incretin Therapy

The SURPASS-CVOT trial confirms that tirzepatide is noninferior to dulaglutide for cardiovascular safety in high-risk type 2 diabetes patients. While superiority was not statistically reached, the study solidifies the cardiovascular profile of dual GIP/GLP-1 agonism compared to established standards of care.
Tailored Digital Emotion Regulation Improves Mental Health in Adults With Congenital Heart Disease: Results of a National Randomized Trial
Posted inCardiology news Psychiatry

Tailored Digital Emotion Regulation Improves Mental Health in Adults With Congenital Heart Disease: Results of a National Randomized Trial

A 3‑arm randomized trial in 524 adults with congenital heart disease found a 4‑week tailored digital emotion‑regulation program produced moderate improvements in emotion regulation and multiple psychosocial outcomes versus usual care; a general program showed delayed, smaller benefits.
Prothrombin Complex Concentrate versus Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery: Evidence Synthesis from the FARES-II Multicenter Randomized Clinical Trial and Related Studies
Posted inCardiology Clinical Updates General Surgery news

Prothrombin Complex Concentrate versus Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery: Evidence Synthesis from the FARES-II Multicenter Randomized Clinical Trial and Related Studies

This review synthesizes evidence demonstrating that 4-factor prothrombin complex concentrate (4F-PCC) offers superior hemostatic efficacy and safety compared to frozen plasma in managing coagulopathic bleeding during cardiac surgery, supported by the recent FARES-II trial and corroborating clinical research.
No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Stroke in Patients with Atrial Fibrillation and Atherosclerosis: Results from the ATIS‑NVAF Randomized Trial
Posted inCardiology Neurology news

No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Stroke in Patients with Atrial Fibrillation and Atherosclerosis: Results from the ATIS‑NVAF Randomized Trial

In older patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic cardiovascular disease, adding a single antiplatelet agent to anticoagulation did not reduce ischemic events but markedly increased bleeding, providing no net clinical benefit versus anticoagulant monotherapy.
No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Ischemic Stroke With Atrial Fibrillation and Atherosclerosis — Higher Bleeding Risk
Posted inCardiology Neurology news

No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Ischemic Stroke With Atrial Fibrillation and Atherosclerosis — Higher Bleeding Risk

In a randomized trial of 316 patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic disease, adding an antiplatelet to anticoagulation did not reduce ischemic events but doubled clinically relevant bleeding compared with anticoagulant monotherapy.